<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00523341</url>
  </required_header>
  <id_info>
    <org_study_id>20060289</org_study_id>
    <nct_id>NCT00523341</nct_id>
  </id_info>
  <brief_title>Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis</brief_title>
  <official_title>An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective was to describe the safety and tolerability of up to 10 years or 7
      years denosumab administration as measured by adverse event monitoring, immunogenicity and
      safety laboratory parameters in participants who previously received denosumab or placebo,
      respectively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>84 months</time_frame>
    <description>A serious adverse event (SAE) is defined as an adverse event that: • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • is other significant medical hazard. Treatment-related adverse events includes only events for which the investigator indicated there was a reasonable possibility they may have been caused by study drug. The following were classified as adverse events of interest (events that are considered to be identified or potential risks of denosumab treatment): positively adjudicated osteonecrosis of the jaw, positively adjudicated atypical femoral fracture, hypocalcemia, adverse events potentially related to hypersensitivity, serious infection (including bacterial cellulitis), malignancy, cardiac disorders, vascular disorders, fracture healing complications, eczema, acute pancreatitis, and musculoskeletal pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Toxicities of Grade ≥ 3</measure>
    <time_frame>84 months</time_frame>
    <description>Laboratory toxicity grading was based on Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Grade 3 indicates severe toxicity and Grade 4 indicates life-threatening toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Antibodies to Denosumab</measure>
    <time_frame>Every 12 months through Month 84</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lumbar Spine Bone Mineral Density by Visit</measure>
    <time_frame>Baseline (of extension study) and months 12, 24, 36, 60 and 84</time_frame>
    <description>Lumbar spine bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Hip Bone Mineral Density by Visit</measure>
    <time_frame>Baseline (of extension study) and months 12, 24, 36, 60 and 84</time_frame>
    <description>Total hip bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Femoral Neck Bone Mineral Density by Visit</measure>
    <time_frame>Baseline (of extension study) and months 12, 24, 36, 60 and 84</time_frame>
    <description>Femoral neck bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in 1/3 Radius Bone Mineral Density by Visit</measure>
    <time_frame>Baseline (of extension study) and months 12, 24, 36, 60 and 84</time_frame>
    <description>1/3 radius bone mineral density was measured in a subset of participants by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Study 20030216 Baseline in Lumbar Spine Bone Mineral Density by Visit</measure>
    <time_frame>Study 20030216 baseline and extension study months 12, 24, 36, 60 and 84</time_frame>
    <description>Lumbar spine bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. Measurements at some time points during the core study 20030216 were only taken in a subset of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Study 20030216 Baseline in Total Hip BMD by Visit</measure>
    <time_frame>Study 20030216 baseline and extension study months 12, 24, 36, 60 and 84</time_frame>
    <description>Total hip bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. Measurements at some time points during the core study 20030216 were only taken in a subset of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Study 20030216 Baseline in Femoral Neck BMD by Visit</measure>
    <time_frame>Study 20030216 baseline and extension study months 12, 24, 36, 60 and 84</time_frame>
    <description>Femoral neck bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. Measurements at some time points during the core study 20030216 were only taken in a subset of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Study 20030216 Baseline in 1/3 Radius BMD by Visit</measure>
    <time_frame>Study 20030216 baseline and extension study months 12, 24, 36, 60, and 84</time_frame>
    <description>1/3 radius BMD was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. Measurements at some time points during the core study 20030216 were only taken in a subset of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New Vertebral Fractures</measure>
    <time_frame>84 months</time_frame>
    <description>A new vertebral fracture, assessed by lateral spine X-ray using Genant semiquantitative scoring method, was identified as an ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4, excluding any fracture associated with high trauma severity or a pathologic fracture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-Vertebral Fractures</measure>
    <time_frame>84 months</time_frame>
    <description>Non-vertebral fractures (osteoporotic) were defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging (MRI) confirming the fracture, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in C-Telopeptide 1 (CTX-1) by Visit</measure>
    <time_frame>Baseline (of extension study), day 10, and months 6, 12, 24, 36, 48, 60, 72, and 84</time_frame>
    <description>Bone turnover markers were collected in a subset of participants who participated in the 20030216 Bone Marker sub-study and in new participants continuing beyond month 24 who were not previously in the Bone Turnover Markers sub-study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Procollagen Type 1 N-telopeptide (P1NP) by Visit</measure>
    <time_frame>Baseline (of extension study), day 10, and months 6, 12, 24, 36, 48, 60, 72, and 84</time_frame>
    <description>Bone turnover markers were collected in a subset of participants who participated in the 20030216 Bone Marker sub-study and in new sparticipants continuing beyond month 24 who were not previously in the Bone Turnover Markers sub-study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Study 20030216 Baseline in CTX-1 by Visit</measure>
    <time_frame>Study 20030216 Baseline and extension study day 10, and months 6, 12, 24, 36, 48, 60, 72, and 84</time_frame>
    <description>Bone turnover markers were collected in a subset of participants who participated in the 20030216 Bone Marker sub-study and in new participants continuing beyond month 24 who were not previously in the Bone Turnover Markers sub-study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Study 20030216 Baseline in P1NP by Visit</measure>
    <time_frame>Study 20030216 Baseline and extension study day 10, and months 6, 12, 24, 36, 48, 60, 72, and 84</time_frame>
    <description>Bone turnover markers were collected in a subset of participants who participated in the 20030216 Bone Marker sub-study and in new participants continuing beyond month 24 who were not previously in the Bone Turnover Markers sub-study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Albumin-adjusted Serum Calcium at Day 10</measure>
    <time_frame>Baseline (of extension study) and day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Denosumab Concentration</measure>
    <time_frame>Baseline (pre-dose in extension study), day 10, and Months 3, 4 and 6 (pre-dose)</time_frame>
    <description>Serum concentrations of denosumab were measured by a validated conventional sandwich enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 0.8 ng/mL. Values of 0 in the table below indicate data below the lower limit of quantification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Cancellous Bone Volume</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Cancellous (trabecular) bone volume is the percent of the total marrow cavity that is occupied by cancellous bone (both mineralized and non-mineralized) measured by quantitative histomorphometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Trabecular Number</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Trabecular number is the number of trabeculae present per lineal mm and is calculated as trabecular bone volume/trabecular thickness. Trabecular number is a measure of trabecular connectivity and decreases with bone loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Trabecular Separation</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Trabecular separation is the mean distance between trabeculae (measured by integrated computer graphics). Trabecular separation increases with trabecular bone loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Trabecular Thickness</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Mean trabecular thickness is a measure of trabecular structure and is calculated as the reciprocal of total bone (trabecular) surfaces. Trabecular thickness is reduced by aging and osteoporosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Cortical Width</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Cortical width is the average width of both inner and outer cortices.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Cancellous Bone Volume by TRAP Histomorphometry</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Cancellous (trabecular) bone volume is the percent of the total marrow cavity that is occupied by cancellous bone (both mineralized and non-mineralized) measured by tartrate-resistant acid phosphatase (TRAP) staining histomorphometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Surface Density</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Surface density is calculated by total bone (trabecular) surfaces / total tissue volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Osteoblast - Osteoid Interface</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Osteoblast - osteoid interface is calculated as osteoblast surface / osteoid surface * 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Osteoid Surface</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Osteoid surface is the percent of bone surface covered in osteoid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Osteoid Thickness</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Osteoid thickness (width) is the mean thickness of osteoid seams on cancellous surfaces. Osteoid thickness is normally &lt;12.5 µm. Increased osteoid thickness suggests abnormal mineralization (osteomalacia).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Wall Thickness</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Wall thickness is the average thickness of trabecular bone structural units (BSU) and is used to assess the overall balance between resorption and formation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Eroded Surface/Bone Surface</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
Eroded surface/bone surface is the percentage of bone surface occupied by eroded (resorption) cavities (Howships lacunae), with or without osteoclasts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Osteoclast Number - Length Based</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
Osteoclast number was measured by quantitative histomorphometry and is expressed per mm of bone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Osteoclast Number - Surface Based</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
Osteoclast number was measured by quantitative histomorphometry and is expressed per 100 mm of bone surface area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Osteoclast Number by TRAP - Length Based</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
Osteoclast number was measured using TRAP staining and is expressed per mm of bone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Osteoclast Number by TRAP - Surface Based</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
Osteoclast number was measured using TRAP staining and is expressed per 100 mm of bone surface.
Da</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Single-label Surface</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. A single label is deposited if formation either started or ended during the interval between the uses of the two courses of tetracycline administration. Single-label surface is expressed as a percentage of total bone surface.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Double-label Surface</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. The presence of double labels indicates that normal bone mineralization was actively occurring over the entire labeling interval. Double-label surface is expressed as a percentage of total bone surface.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Mineralizing Surface</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. Total mineralizing surfaces (MS) include all double and half of single-labeled surfaces. MS is expressed as a percentage of total bone surface.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Mineral Apposition Rate</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. The mineral apposition rate (MAR) is the avarage rate at which new bone mineral is being added on any actively forming surface. MAR is calculated as the average distance between visible labels, divided by the labeling interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Adjusted Apposition Rate</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. The mineral apposition rate (MAR) is the average rate at which new bone mineral is being added on any actively forming surface. Adjusted MAR is calculated as: (average distance between visible labels / labeling interval) * (total mineralizing surface/total bone surface).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Bone Formation Rate - Surface Based</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. Bone formation rate - surface based is the calculated rate at which cancellous bone surface is being replaced annually, derived from the Mineral Appositional Rate * 365 * (relative mineralizing surface / total bone surface).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Bone Formation Rate - Volume Based</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. Bone formation rate - volume based is the calculated rate at which cancellous bone volume is being replaced annually, derived from the Mineral Appositional Rate * 365 * (relative mineralizing surface / total bone volume).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Formation Period</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. Formation period (FP) is the mean time required to rebuild a new bone structural unit or osteon from the cement line back to the bone surface at a single location, and is given by wall width / adjusted apposition rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Activation Frequency</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. The average time that it takes for a new remodeling cycle to begin on any point on a cancellous surface is called the activation frequency. Activation frequency is calculated as the bone formation rate / wall width.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Osteoid Volume</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
Osteoid volume is the percentage of a given volume of bone tissue that consists of unmineralized bone (osteoid).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histomorphometry: Mineralization Lag Time</measure>
    <time_frame>Month 24 and month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken.
Mineralization lag time is the average time interval between osteoid formation and its subsequent mineralization and is calculated by dividing the osteoid width by the apposition rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histology at Month 24</measure>
    <time_frame>Month 24</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histology to determine if there were any histological abnormalities in the bone. Results are reported for the number of biopsies with normal bone micro-architecture: normal lamellar bone, normal mineralization, and osteoid, and biopsies with abnormal bone histology: osteomalacia, marrow fibrosis, or woven bone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Histology at Month 84</measure>
    <time_frame>Month 84</time_frame>
    <description>Bone biopsy samples were prepared according to standard procedures for bone histology to determine if there were any histological abnormalities in the bone. Results are reported for the number of biopsies with normal bone micro-architecture: normal lamellar bone, normal mineralization, and osteoid, and biopsies with abnormal bone histology: osteomalacia, marrow fibrosis, or woven bone.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4550</enrollment>
  <condition>Osteopenia</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 60 mg subcutaneous injection of denosumab every 6 months for seven years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>Administered by subcutaneous injection once every 6 months.</description>
    <arm_group_label>Denosumab</arm_group_label>
    <other_name>AMG 162</other_name>
    <other_name>Prolia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Postmenopausal women who have attended the 20030216 (NCT00089791) study month 36 visit will
        be eligible to participate if they meet the inclusion and exclusion criteria given below.

        Inclusion Criteria

          -  Subjects must sign the informed consent before any study specific procedures are
             performed and agree to receive denosumab 60 mg subcutaneous injection every 6 months

          -  Subjects must not have discontinued investigational product during the 20030216 study
             and must have attended the 20030216 study month 36 visit

          -  Subjects must be re-consented prior to (or at) the 24 month visit for participation
             beyond month 24.

        Exclusion Criteria

          -  Permanently non-ambulatory subjects (use of an assistive device eg, cane, walker, etc.
             is permitted)

          -  Missed 2 or more investigational product doses during the 20030216 study

          -  Any disorder that, in the opinion of the investigator, may compromise the ability of
             the subject to give written informed consent and/or comply with study procedures

          -  Developed sensitivity to mammalian cell derived drug products during the 20030216
             study

          -  Unable to tolerate calcium supplementation during the last 6 months of participation
             in the 20030216 study (between the month 30 and month 36 20030216 study visits)

          -  Currently receiving any investigational product other than denosumab or having
             received any investigational product during the 20030216 study

          -  Current use of the following osteoporosis agents: bisphosphonates, calcitonin,
             fluoride, parathyroid hormone, selective estrogen receptor modulators, systemic oral
             or transdermal estrogen (except vaginal preparations and estrogen creams which are
             acceptable), strontium, or tibolone

          -  For bone biopsy sub-study subjects only: known or suspected sensitivity or
             contraindication to tetracycline derivatives
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>94 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>Former Serbia and Montenegro</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Malta</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2007</study_first_submitted>
  <study_first_submitted_qc>August 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2007</study_first_posted>
  <results_first_submitted>June 1, 2016</results_first_submitted>
  <results_first_submitted_qc>June 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 12, 2016</results_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postmenopausal osteoporosis</keyword>
  <keyword>low bone density</keyword>
  <keyword>fractures</keyword>
  <keyword>low bone mass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was an extension study open to participants who had completed core study 20030216 (NCT00089791). The study was conducted at 178 centers in North America, South America, Europe, Australia, and New Zealand. Participants were enrolled from 7 August 2007 to 20 June 2008.</recruitment_details>
      <pre_assignment_details>All participants received open-label denosumab during this study. Results are reported by the Study 20030216 randomized treatment groups (placebo versus denosumab).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo / Denosumab</title>
          <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
        </group>
        <group group_id="P2">
          <title>Denosumab / Denosumab</title>
          <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2207"/>
                <participants group_id="P2" count="2343"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="2206"/>
                <participants group_id="P2" count="2343"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1283"/>
                <participants group_id="P2" count="1343"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="924"/>
                <participants group_id="P2" count="1000"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="399"/>
                <participants group_id="P2" count="427"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
                <participants group_id="P2" count="198"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="155"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="110"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Requirement for Alternative Therapy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligibility Determined</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo / Denosumab</title>
          <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
        </group>
        <group group_id="B2">
          <title>Denosumab / Denosumab</title>
          <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2207"/>
            <count group_id="B2" value="2343"/>
            <count group_id="B3" value="4550"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.8" spread="5.1"/>
                    <measurement group_id="B2" value="74.9" spread="5.0"/>
                    <measurement group_id="B3" value="74.8" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>60 - 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 - 69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="326"/>
                    <measurement group_id="B2" value="320"/>
                    <measurement group_id="B3" value="646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70 - 74 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="672"/>
                    <measurement group_id="B2" value="716"/>
                    <measurement group_id="B3" value="1388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1151"/>
                    <measurement group_id="B2" value="1258"/>
                    <measurement group_id="B3" value="2409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2207"/>
                    <measurement group_id="B2" value="2343"/>
                    <measurement group_id="B3" value="4550"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2063"/>
                    <measurement group_id="B2" value="2169"/>
                    <measurement group_id="B3" value="4232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bone Mineral Density T-score</title>
          <description>The T-score is the bone mineral density (BMD) at the site when compared to that of a healthy thirty-year-old.
Normal is a T-score of −1.0 or higher; Osteopenia is defined as between −1.0 and −2.5; Osteoporosis is defined as −2.5 or lower, meaning a bone density that is two and a half standard deviations below the mean of a thirty-year-old man/woman.</description>
          <units>T-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Lumbar spine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.81" spread="0.75"/>
                    <measurement group_id="B2" value="-2.14" spread="0.80"/>
                    <measurement group_id="B3" value="-2.47" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total hip</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-1.93" spread="0.80"/>
                    <measurement group_id="B2" value="-1.50" spread="0.79"/>
                    <measurement group_id="B3" value="-1.71" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral neck</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.17" spread="0.72"/>
                    <measurement group_id="B2" value="-1.83" spread="0.75"/>
                    <measurement group_id="B3" value="-1.99" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bone Mineral Density T-score at Study 20030216 Baseline</title>
          <units>T-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Lumbar spine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.84" spread="0.68"/>
                    <measurement group_id="B2" value="-2.83" spread="0.67"/>
                    <measurement group_id="B3" value="-2.83" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total hip</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-1.85" spread="0.79"/>
                    <measurement group_id="B2" value="-1.85" spread="0.79"/>
                    <measurement group_id="B3" value="-1.85" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral neck</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-2.11" spread="0.71"/>
                    <measurement group_id="B2" value="-2.11" spread="0.71"/>
                    <measurement group_id="B3" value="-2.11" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Any Historical Fracture at Age ≥ 55 Years</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1089"/>
                    <measurement group_id="B2" value="1133"/>
                    <measurement group_id="B3" value="2222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <description>A serious adverse event (SAE) is defined as an adverse event that: • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • is other significant medical hazard. Treatment-related adverse events includes only events for which the investigator indicated there was a reasonable possibility they may have been caused by study drug. The following were classified as adverse events of interest (events that are considered to be identified or potential risks of denosumab treatment): positively adjudicated osteonecrosis of the jaw, positively adjudicated atypical femoral fracture, hypocalcemia, adverse events potentially related to hypersensitivity, serious infection (including bacterial cellulitis), malignancy, cardiac disorders, vascular disorders, fracture healing complications, eczema, acute pancreatitis, and musculoskeletal pain.</description>
        <time_frame>84 months</time_frame>
        <population>All participants who received at least one dose of denosumab.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <description>A serious adverse event (SAE) is defined as an adverse event that: • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • is other significant medical hazard. Treatment-related adverse events includes only events for which the investigator indicated there was a reasonable possibility they may have been caused by study drug. The following were classified as adverse events of interest (events that are considered to be identified or potential risks of denosumab treatment): positively adjudicated osteonecrosis of the jaw, positively adjudicated atypical femoral fracture, hypocalcemia, adverse events potentially related to hypersensitivity, serious infection (including bacterial cellulitis), malignancy, cardiac disorders, vascular disorders, fracture healing complications, eczema, acute pancreatitis, and musculoskeletal pain.</description>
          <population>All participants who received at least one dose of denosumab.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2206"/>
                <count group_id="O2" value="2343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event (AE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2070"/>
                    <measurement group_id="O2" value="2173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="945"/>
                    <measurement group_id="O2" value="1014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to study discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to discontinuation of denosumab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related adverse events (TRAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                    <measurement group_id="O2" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious treatment-related adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal treatment-related adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TRAE leading to study discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TRAE leading to discontinuation of denosumab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positively adjudicated osteonecrosis of the jaw</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positively adjudicated atypical femoral fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypocalcaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs potentially related to hypersensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260"/>
                    <measurement group_id="O2" value="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious bacterial cellulitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                    <measurement group_id="O2" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="449"/>
                    <measurement group_id="O2" value="492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="693"/>
                    <measurement group_id="O2" value="732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fracture healing complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eczema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute pancreatitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1125"/>
                    <measurement group_id="O2" value="1206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Laboratory Toxicities of Grade ≥ 3</title>
        <description>Laboratory toxicity grading was based on Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Grade 3 indicates severe toxicity and Grade 4 indicates life-threatening toxicity.</description>
        <time_frame>84 months</time_frame>
        <population>All participants who received at least 1 dose of denosumab</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Toxicities of Grade ≥ 3</title>
          <description>Laboratory toxicity grading was based on Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Grade 3 indicates severe toxicity and Grade 4 indicates life-threatening toxicity.</description>
          <population>All participants who received at least 1 dose of denosumab</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2206"/>
                <count group_id="O2" value="2343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Low sodium - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low sodium - Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High potassium - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High potassium - Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low potassium - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low magnesium - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low magnesium - Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High calcium - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High calcium - Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High corrected calcium - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High corrected calcium - Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low phosphorus - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Creatinine - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High aspartate amino transferase (AST) - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High aspartate amino transferase (AST) - Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High alanine amino transferase (ALT) - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High alanine amino transferase (ALT) - Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High total bilirubin - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low albumin - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High glucose - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High glucose - Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low glucose - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low glucose - Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low hemoglobin - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low platelets - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low platelets - Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low white blood cells - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low white blood cells - Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low lymphocytes - Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low lymphocytes - Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Antibodies to Denosumab</title>
        <time_frame>Every 12 months through Month 84</time_frame>
        <population>All participants who received at least 1 dose of denosumab</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Antibodies to Denosumab</title>
          <population>All participants who received at least 1 dose of denosumab</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2206"/>
                <count group_id="O2" value="2343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lumbar Spine Bone Mineral Density by Visit</title>
        <description>Lumbar spine bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
        <time_frame>Baseline (of extension study) and months 12, 24, 36, 60 and 84</time_frame>
        <population>Participants with an Extension Study baseline and at least 1 post-baseline DXA BMD measurement. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lumbar Spine Bone Mineral Density by Visit</title>
          <description>Lumbar spine bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
          <population>Participants with an Extension Study baseline and at least 1 post-baseline DXA BMD measurement. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2089"/>
                <count group_id="O2" value="2210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12 (n = 2040, 2168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="5.0" upper_limit="5.3"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.8" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n = 1935, 2061)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="7.5" upper_limit="7.9"/>
                    <measurement group_id="O2" value="3.5" lower_limit="3.4" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n = 1497, 1607)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="9.1" upper_limit="9.6"/>
                    <measurement group_id="O2" value="4.9" lower_limit="4.7" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 (n = 1472, 1567)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="12.7" upper_limit="13.3"/>
                    <measurement group_id="O2" value="7.9" lower_limit="7.6" upper_limit="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 1223, 1264)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="16.1" upper_limit="16.9"/>
                    <measurement group_id="O2" value="10.8" lower_limit="10.4" upper_limit="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Hip Bone Mineral Density by Visit</title>
        <description>Total hip bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
        <time_frame>Baseline (of extension study) and months 12, 24, 36, 60 and 84</time_frame>
        <population>Participants with an Extension Study baseline and at least 1 post-baseline DXA BMD measurement. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Hip Bone Mineral Density by Visit</title>
          <description>Total hip bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
          <population>Participants with an Extension Study baseline and at least 1 post-baseline DXA BMD measurement. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2089"/>
                <count group_id="O2" value="2210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12 (n = 2029, 2160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.8" upper_limit="3.1"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.7" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n = 1918, 2045)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="4.0" upper_limit="4.2"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1.3" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n = 1475, 1591)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="4.7" upper_limit="5.0"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.7" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 (n = 1439, 1538)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="6.0" upper_limit="6.4"/>
                    <measurement group_id="O2" value="2.6" lower_limit="2.4" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 1200, 1232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="7.1" upper_limit="7.6"/>
                    <measurement group_id="O2" value="3.4" lower_limit="3.2" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Femoral Neck Bone Mineral Density by Visit</title>
        <description>Femoral neck bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
        <time_frame>Baseline (of extension study) and months 12, 24, 36, 60 and 84</time_frame>
        <population>Participants with an Extension Study baseline and at least 1 post-baseline DXA BMD measurement. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Femoral Neck Bone Mineral Density by Visit</title>
          <description>Femoral neck bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
          <population>Participants with an Extension Study baseline and at least 1 post-baseline DXA BMD measurement. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2089"/>
                <count group_id="O2" value="2210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12 (n = 2029, 2160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.9" upper_limit="2.3"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.7" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n = 1918, 2045)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="3.1" upper_limit="3.4"/>
                    <measurement group_id="O2" value="1.2" lower_limit="1.0" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n = 1475, 1591)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="3.8" upper_limit="4.3"/>
                    <measurement group_id="O2" value="1.7" lower_limit="1.5" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 (n = 1439, 1538)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" lower_limit="5.4" upper_limit="5.9"/>
                    <measurement group_id="O2" value="2.8" lower_limit="2.6" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 1200, 1232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="6.8" upper_limit="7.4"/>
                    <measurement group_id="O2" value="3.8" lower_limit="3.5" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in 1/3 Radius Bone Mineral Density by Visit</title>
        <description>1/3 radius bone mineral density was measured in a subset of participants by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
        <time_frame>Baseline (of extension study) and months 12, 24, 36, 60 and 84</time_frame>
        <population>Participants in the DXA substudy with an Extension Study baseline and at least 1 post-baseline DXA BMD measurement. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in 1/3 Radius Bone Mineral Density by Visit</title>
          <description>1/3 radius bone mineral density was measured in a subset of participants by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.</description>
          <population>Participants in the DXA substudy with an Extension Study baseline and at least 1 post-baseline DXA BMD measurement. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="449"/>
                <count group_id="O2" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12 (n = 114, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-0.2" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.1" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n = 108, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="-0.4" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-0.4" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n = 73, 93)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.5" upper_limit="2.0"/>
                    <measurement group_id="O2" value="0.6" lower_limit="-0.1" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 (n = 59, 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="0.9" upper_limit="2.7"/>
                    <measurement group_id="O2" value="1.4" lower_limit="0.6" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 39, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0.9" upper_limit="3.6"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-0.1" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Study 20030216 Baseline in Lumbar Spine Bone Mineral Density by Visit</title>
        <description>Lumbar spine bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. Measurements at some time points during the core study 20030216 were only taken in a subset of participants.</description>
        <time_frame>Study 20030216 baseline and extension study months 12, 24, 36, 60 and 84</time_frame>
        <population>Participants with an Extension Study baseline and at least 1 post-baseline DXA BMD measurement. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Study 20030216 Baseline in Lumbar Spine Bone Mineral Density by Visit</title>
          <description>Lumbar spine bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. Measurements at some time points during the core study 20030216 were only taken in a subset of participants.</description>
          <population>Participants with an Extension Study baseline and at least 1 post-baseline DXA BMD measurement. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2089"/>
                <count group_id="O2" value="2210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12 (n = 2030, 2148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="5.6" upper_limit="6.1"/>
                    <measurement group_id="O2" value="11.9" lower_limit="11.7" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n = 1924, 2041)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" lower_limit="8.1" upper_limit="8.7"/>
                    <measurement group_id="O2" value="13.7" lower_limit="13.4" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n = 1487, 1589)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="9.8" upper_limit="10.4"/>
                    <measurement group_id="O2" value="15.2" lower_limit="14.9" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 (n = 1464, 1551)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" lower_limit="13.4" upper_limit="14.1"/>
                    <measurement group_id="O2" value="18.4" lower_limit="18.1" upper_limit="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 1216, 1251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="16.8" upper_limit="17.8"/>
                    <measurement group_id="O2" value="21.7" lower_limit="21.2" upper_limit="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Study 20030216 Baseline in Total Hip BMD by Visit</title>
        <description>Total hip bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. Measurements at some time points during the core study 20030216 were only taken in a subset of participants.</description>
        <time_frame>Study 20030216 baseline and extension study months 12, 24, 36, 60 and 84</time_frame>
        <population>Participants with an Extension Study baseline and at least 1 post-baseline DXA BMD measurement. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Study 20030216 Baseline in Total Hip BMD by Visit</title>
          <description>Total hip bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. Measurements at some time points during the core study 20030216 were only taken in a subset of participants.</description>
          <population>Participants with an Extension Study baseline and at least 1 post-baseline DXA BMD measurement. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2089"/>
                <count group_id="O2" value="2210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12 (n = 2006, 2132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.6" upper_limit="1.9"/>
                    <measurement group_id="O2" value="6.4" lower_limit="6.3" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n = 1895, 2017)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="2.7" upper_limit="3.0"/>
                    <measurement group_id="O2" value="7.1" lower_limit="6.9" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n = 1457, 1567)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="3.4" upper_limit="3.8"/>
                    <measurement group_id="O2" value="7.5" lower_limit="7.3" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 (n = 1424, 1518)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="4.7" upper_limit="5.2"/>
                    <measurement group_id="O2" value="8.4" lower_limit="8.1" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 1189, 1215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="5.8" upper_limit="6.4"/>
                    <measurement group_id="O2" value="9.2" lower_limit="8.9" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Study 20030216 Baseline in Femoral Neck BMD by Visit</title>
        <description>Femoral neck bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. Measurements at some time points during the core study 20030216 were only taken in a subset of participants.</description>
        <time_frame>Study 20030216 baseline and extension study months 12, 24, 36, 60 and 84</time_frame>
        <population>Participants with an Extension Study baseline and at least 1 post-baseline DXA BMD measurement. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Study 20030216 Baseline in Femoral Neck BMD by Visit</title>
          <description>Femoral neck bone mineral density was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. Measurements at some time points during the core study 20030216 were only taken in a subset of participants.</description>
          <population>Participants with an Extension Study baseline and at least 1 post-baseline DXA BMD measurement. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2089"/>
                <count group_id="O2" value="2210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12 (n = 2006, 2132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.2" upper_limit="1.7"/>
                    <measurement group_id="O2" value="5.8" lower_limit="5.6" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n = 1895, 2017)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="2.3" upper_limit="2.8"/>
                    <measurement group_id="O2" value="6.2" lower_limit="6.0" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n = 1457, 1567)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="3.1" upper_limit="3.6"/>
                    <measurement group_id="O2" value="6.7" lower_limit="6.5" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 (n = 1424, 1518)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="4.7" upper_limit="5.3"/>
                    <measurement group_id="O2" value="7.9" lower_limit="7.6" upper_limit="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 1189, 1215)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="6.0" upper_limit="6.8"/>
                    <measurement group_id="O2" value="9.0" lower_limit="8.6" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Study 20030216 Baseline in 1/3 Radius BMD by Visit</title>
        <description>1/3 radius BMD was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. Measurements at some time points during the core study 20030216 were only taken in a subset of participants.</description>
        <time_frame>Study 20030216 baseline and extension study months 12, 24, 36, 60, and 84</time_frame>
        <population>Participants in the DXA substudy with an Extension Study baseline and at least 1 post-baseline DXA BMD measurement. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Study 20030216 Baseline in 1/3 Radius BMD by Visit</title>
          <description>1/3 radius BMD was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center. Measurements at some time points during the core study 20030216 were only taken in a subset of participants.</description>
          <population>Participants in the DXA substudy with an Extension Study baseline and at least 1 post-baseline DXA BMD measurement. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="449"/>
                <count group_id="O2" value="467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12 (n = 113, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-1.7" upper_limit="-0.3"/>
                    <measurement group_id="O2" value="2.6" lower_limit="1.9" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n = 107, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" lower_limit="-1.9" upper_limit="-0.4"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.4" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n = 73, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-1.1" upper_limit="0.7"/>
                    <measurement group_id="O2" value="2.4" lower_limit="1.6" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 (n = 59, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-0.7" upper_limit="1.3"/>
                    <measurement group_id="O2" value="3.3" lower_limit="2.4" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 39, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="-0.8" upper_limit="2.1"/>
                    <measurement group_id="O2" value="2.8" lower_limit="1.6" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New Vertebral Fractures</title>
        <description>A new vertebral fracture, assessed by lateral spine X-ray using Genant semiquantitative scoring method, was identified as an ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4, excluding any fracture associated with high trauma severity or a pathologic fracture.</description>
        <time_frame>84 months</time_frame>
        <population>All participants enrolled in the extension study who have vertebral X-ray assessment at the extension baseline and at least 1 post-extension baseline visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New Vertebral Fractures</title>
          <description>A new vertebral fracture, assessed by lateral spine X-ray using Genant semiquantitative scoring method, was identified as an ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4, excluding any fracture associated with high trauma severity or a pathologic fracture.</description>
          <population>All participants enrolled in the extension study who have vertebral X-ray assessment at the extension baseline and at least 1 post-extension baseline visit.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1991"/>
                <count group_id="O2" value="2116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-Vertebral Fractures</title>
        <description>Non-vertebral fractures (osteoporotic) were defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging (MRI) confirming the fracture, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.</description>
        <time_frame>84 months</time_frame>
        <population>All enrolled participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-Vertebral Fractures</title>
          <description>Non-vertebral fractures (osteoporotic) were defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging (MRI) confirming the fracture, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.</description>
          <population>All enrolled participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2207"/>
                <count group_id="O2" value="2343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in C-Telopeptide 1 (CTX-1) by Visit</title>
        <description>Bone turnover markers were collected in a subset of participants who participated in the 20030216 Bone Marker sub-study and in new participants continuing beyond month 24 who were not previously in the Bone Turnover Markers sub-study.</description>
        <time_frame>Baseline (of extension study), day 10, and months 6, 12, 24, 36, 48, 60, 72, and 84</time_frame>
        <population>Participants who received at least 1 dose of denosumab and enrolled in the bone turnover marker substudy at screening or Month 24 in Study 20060289. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in C-Telopeptide 1 (CTX-1) by Visit</title>
          <description>Bone turnover markers were collected in a subset of participants who participated in the 20030216 Bone Marker sub-study and in new participants continuing beyond month 24 who were not previously in the Bone Turnover Markers sub-study.</description>
          <population>Participants who received at least 1 dose of denosumab and enrolled in the bone turnover marker substudy at screening or Month 24 in Study 20060289. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="318"/>
                <count group_id="O2" value="342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 10 (n = 26, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-90" lower_limit="-93" upper_limit="-85"/>
                    <measurement group_id="O2" value="-72" lower_limit="-86" upper_limit="-47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n = 30, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-85" lower_limit="-91" upper_limit="-73"/>
                    <measurement group_id="O2" value="-26" lower_limit="-63" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n = 27, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-75" lower_limit="-90" upper_limit="-54"/>
                    <measurement group_id="O2" value="-13" lower_limit="-37" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n = 27, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67" lower_limit="-84" upper_limit="-29"/>
                    <measurement group_id="O2" value="10" lower_limit="-27" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n = 68, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59" lower_limit="-84" upper_limit="-28"/>
                    <measurement group_id="O2" value="2" lower_limit="-32" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48 (n = 62, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-58" lower_limit="-84" upper_limit="-12"/>
                    <measurement group_id="O2" value="0" lower_limit="-46" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 (n = 59, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-65" lower_limit="-90" upper_limit="-19"/>
                    <measurement group_id="O2" value="0" lower_limit="-47" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 72 (n = 56, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60" lower_limit="-85" upper_limit="-16"/>
                    <measurement group_id="O2" value="-1" lower_limit="-47" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 41, 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-64" lower_limit="-86" upper_limit="-28"/>
                    <measurement group_id="O2" value="-6" lower_limit="-26" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Procollagen Type 1 N-telopeptide (P1NP) by Visit</title>
        <description>Bone turnover markers were collected in a subset of participants who participated in the 20030216 Bone Marker sub-study and in new sparticipants continuing beyond month 24 who were not previously in the Bone Turnover Markers sub-study.</description>
        <time_frame>Baseline (of extension study), day 10, and months 6, 12, 24, 36, 48, 60, 72, and 84</time_frame>
        <population>Participants who received at least 1 dose of denosumab and enrolled in the bone turnover marker substudy at screening or Month 24 in Study 20060289. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Procollagen Type 1 N-telopeptide (P1NP) by Visit</title>
          <description>Bone turnover markers were collected in a subset of participants who participated in the 20030216 Bone Marker sub-study and in new sparticipants continuing beyond month 24 who were not previously in the Bone Turnover Markers sub-study.</description>
          <population>Participants who received at least 1 dose of denosumab and enrolled in the bone turnover marker substudy at screening or Month 24 in Study 20060289. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="318"/>
                <count group_id="O2" value="342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 10 (n = 30, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="-5" upper_limit="30"/>
                    <measurement group_id="O2" value="14" lower_limit="-1" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n = 30, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-71" lower_limit="-78" upper_limit="-62"/>
                    <measurement group_id="O2" value="-23" lower_limit="-50" upper_limit="-2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n = 26, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67" lower_limit="-76" upper_limit="-57"/>
                    <measurement group_id="O2" value="7" lower_limit="-15" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n = 27, 47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-63" lower_limit="-77" upper_limit="-41"/>
                    <measurement group_id="O2" value="11" lower_limit="-17" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n = 69, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57" lower_limit="-67" upper_limit="-29"/>
                    <measurement group_id="O2" value="29" lower_limit="-6" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48 (n = 61, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60" lower_limit="-70" upper_limit="-41"/>
                    <measurement group_id="O2" value="8" lower_limit="-21" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 (n = 61, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54" lower_limit="-72" upper_limit="-35"/>
                    <measurement group_id="O2" value="30" lower_limit="-6" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 72 (n = 55, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50" lower_limit="-60" upper_limit="-36"/>
                    <measurement group_id="O2" value="44" lower_limit="3" upper_limit="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 48, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59" lower_limit="-73" upper_limit="-40"/>
                    <measurement group_id="O2" value="32" lower_limit="-4" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Study 20030216 Baseline in CTX-1 by Visit</title>
        <description>Bone turnover markers were collected in a subset of participants who participated in the 20030216 Bone Marker sub-study and in new participants continuing beyond month 24 who were not previously in the Bone Turnover Markers sub-study.</description>
        <time_frame>Study 20030216 Baseline and extension study day 10, and months 6, 12, 24, 36, 48, 60, 72, and 84</time_frame>
        <population>Participants who received at least 1 dose of denosumab and enrolled in the bone turnover marker substudy at screening or Month 24 in Study 20060289. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Study 20030216 Baseline in CTX-1 by Visit</title>
          <description>Bone turnover markers were collected in a subset of participants who participated in the 20030216 Bone Marker sub-study and in new participants continuing beyond month 24 who were not previously in the Bone Turnover Markers sub-study.</description>
          <population>Participants who received at least 1 dose of denosumab and enrolled in the bone turnover marker substudy at screening or Month 24 in Study 20060289. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="318"/>
                <count group_id="O2" value="342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 10 (n = 26, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-90" lower_limit="-91" upper_limit="-78"/>
                    <measurement group_id="O2" value="-91" lower_limit="-93" upper_limit="-86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n = 32, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-83" lower_limit="-90" upper_limit="-72"/>
                    <measurement group_id="O2" value="-77" lower_limit="-87" upper_limit="-49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n = 27, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-77" lower_limit="-91" upper_limit="-45"/>
                    <measurement group_id="O2" value="-63" lower_limit="-87" upper_limit="-11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n = 28, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-65" lower_limit="-80" upper_limit="-24"/>
                    <measurement group_id="O2" value="-53" lower_limit="-82" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n = 289, 313)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-71" lower_limit="-88" upper_limit="-40"/>
                    <measurement group_id="O2" value="-52" lower_limit="-86" upper_limit="-4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48 (n = 274, 290)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70" lower_limit="-88" upper_limit="-36"/>
                    <measurement group_id="O2" value="-61" lower_limit="-85" upper_limit="-24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 (n = 268, 276)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67" lower_limit="-88" upper_limit="-25"/>
                    <measurement group_id="O2" value="-53" lower_limit="-86" upper_limit="-18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 72 (n = 243, 248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-69" lower_limit="-88" upper_limit="-32"/>
                    <measurement group_id="O2" value="-59" lower_limit="-86" upper_limit="-21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 217, 216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-63" lower_limit="-88" upper_limit="-19"/>
                    <measurement group_id="O2" value="-53" lower_limit="-84" upper_limit="-12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Study 20030216 Baseline in P1NP by Visit</title>
        <description>Bone turnover markers were collected in a subset of participants who participated in the 20030216 Bone Marker sub-study and in new participants continuing beyond month 24 who were not previously in the Bone Turnover Markers sub-study.</description>
        <time_frame>Study 20030216 Baseline and extension study day 10, and months 6, 12, 24, 36, 48, 60, 72, and 84</time_frame>
        <population>Participants who received at least 1 dose of denosumab and enrolled in the bone turnover marker substudy at screening or Month 24 in Study 20060289. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Study 20030216 Baseline in P1NP by Visit</title>
          <description>Bone turnover markers were collected in a subset of participants who participated in the 20030216 Bone Marker sub-study and in new participants continuing beyond month 24 who were not previously in the Bone Turnover Markers sub-study.</description>
          <population>Participants who received at least 1 dose of denosumab and enrolled in the bone turnover marker substudy at screening or Month 24 in Study 20060289. &quot;n&quot; indicates the number of participants with available data at each time point.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="318"/>
                <count group_id="O2" value="342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 10 (n = 30, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="-14" upper_limit="34"/>
                    <measurement group_id="O2" value="-59" lower_limit="-74" upper_limit="-22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n = 32, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-74" lower_limit="-80" upper_limit="-67"/>
                    <measurement group_id="O2" value="-75" lower_limit="-80" upper_limit="-55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n = 26, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-74" lower_limit="-79" upper_limit="-51"/>
                    <measurement group_id="O2" value="-63" lower_limit="-76" upper_limit="-36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n = 28, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67" lower_limit="-75" upper_limit="-51"/>
                    <measurement group_id="O2" value="-56" lower_limit="-72" upper_limit="-30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n = 70, 83)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59" lower_limit="-75" upper_limit="-37"/>
                    <measurement group_id="O2" value="-60" lower_limit="-71" upper_limit="-40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48 (n = 61, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67" lower_limit="-75" upper_limit="-46"/>
                    <measurement group_id="O2" value="-63" lower_limit="-77" upper_limit="-42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 (n = 61, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-62" lower_limit="-75" upper_limit="-42"/>
                    <measurement group_id="O2" value="-55" lower_limit="-74" upper_limit="-30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 72 (n = 56, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-62" lower_limit="-71" upper_limit="-35"/>
                    <measurement group_id="O2" value="-55" lower_limit="-70" upper_limit="-27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n =49, 53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-68" lower_limit="-78" upper_limit="-56"/>
                    <measurement group_id="O2" value="-57" lower_limit="-74" upper_limit="-38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Albumin-adjusted Serum Calcium at Day 10</title>
        <time_frame>Baseline (of extension study) and day 10</time_frame>
        <population>Participants who had a calcium corrected by albumin measurement within the Day 10 visit window up to May 31, 2008.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Albumin-adjusted Serum Calcium at Day 10</title>
          <population>Participants who had a calcium corrected by albumin measurement within the Day 10 visit window up to May 31, 2008.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2027"/>
                <count group_id="O2" value="2154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" lower_limit="-6.1" upper_limit="0.0"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-5.1" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Denosumab Concentration</title>
        <description>Serum concentrations of denosumab were measured by a validated conventional sandwich enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 0.8 ng/mL. Values of 0 in the table below indicate data below the lower limit of quantification.</description>
        <time_frame>Baseline (pre-dose in extension study), day 10, and Months 3, 4 and 6 (pre-dose)</time_frame>
        <population>Participants who participated in the Study 20030216 PK substudy, for whom dosing information was not missing and for whom sampling was within 14 days of specified sampling times.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Denosumab Concentration</title>
          <description>Serum concentrations of denosumab were measured by a validated conventional sandwich enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) was 0.8 ng/mL. Values of 0 in the table below indicate data below the lower limit of quantification.</description>
          <population>Participants who participated in the Study 20030216 PK substudy, for whom dosing information was not missing and for whom sampling was within 14 days of specified sampling times.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n = 97, 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="113" spread="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10 (n = 92, 106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5890" spread="2010"/>
                    <measurement group_id="O2" value="6010" spread="2530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n = 81, 92)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1000" spread="560"/>
                    <measurement group_id="O2" value="1190" spread="690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 4 (n = 87, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="429" spread="378"/>
                    <measurement group_id="O2" value="554" spread="480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n = 87, 103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" spread="61.7"/>
                    <measurement group_id="O2" value="66.0" spread="147.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Cancellous Bone Volume</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Cancellous (trabecular) bone volume is the percent of the total marrow cavity that is occupied by cancellous bone (both mineralized and non-mineralized) measured by quantitative histomorphometry.</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available cancellous bone volume data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Cancellous Bone Volume</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Cancellous (trabecular) bone volume is the percent of the total marrow cavity that is occupied by cancellous bone (both mineralized and non-mineralized) measured by quantitative histomorphometry.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available cancellous bone volume data.</population>
          <units>percentage of total bone tissue volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 13, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.253" spread="6.065"/>
                    <measurement group_id="O2" value="14.640" spread="6.979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="16.358" spread="4.438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Trabecular Number</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Trabecular number is the number of trabeculae present per lineal mm and is calculated as trabecular bone volume/trabecular thickness. Trabecular number is a measure of trabecular connectivity and decreases with bone loss.</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available trabecular number data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Trabecular Number</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Trabecular number is the number of trabeculae present per lineal mm and is calculated as trabecular bone volume/trabecular thickness. Trabecular number is a measure of trabecular connectivity and decreases with bone loss.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available trabecular number data.</population>
          <units>1/mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 13, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.005" spread="0.242"/>
                    <measurement group_id="O2" value="0.904" spread="0.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n = 0, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="1.235" spread="0.254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Trabecular Separation</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Trabecular separation is the mean distance between trabeculae (measured by integrated computer graphics). Trabecular separation increases with trabecular bone loss.</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available trabecular separation data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Trabecular Separation</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Trabecular separation is the mean distance between trabeculae (measured by integrated computer graphics). Trabecular separation increases with trabecular bone loss.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available trabecular separation data.</population>
          <units>μm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 13, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="919.693" spread="358.238"/>
                    <measurement group_id="O2" value="1033.416" spread="352.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="708.669" spread="171.782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Trabecular Thickness</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Mean trabecular thickness is a measure of trabecular structure and is calculated as the reciprocal of total bone (trabecular) surfaces. Trabecular thickness is reduced by aging and osteoporosis.</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available trabecular thickness data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Trabecular Thickness</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Mean trabecular thickness is a measure of trabecular structure and is calculated as the reciprocal of total bone (trabecular) surfaces. Trabecular thickness is reduced by aging and osteoporosis.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available trabecular thickness data.</population>
          <units>μm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 13, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.878" spread="51.859"/>
                    <measurement group_id="O2" value="156.335" spread="48.567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="132.965" spread="28.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Cortical Width</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Cortical width is the average width of both inner and outer cortices.</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available cortical width data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Cortical Width</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Cortical width is the average width of both inner and outer cortices.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available cortical width data.</population>
          <units>μm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 13, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="622.22" spread="246.70"/>
                    <measurement group_id="O2" value="707.69" spread="237.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="786.19" spread="279.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Cancellous Bone Volume by TRAP Histomorphometry</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Cancellous (trabecular) bone volume is the percent of the total marrow cavity that is occupied by cancellous bone (both mineralized and non-mineralized) measured by tartrate-resistant acid phosphatase (TRAP) staining histomorphometry.</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available cancellous bone volume data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Cancellous Bone Volume by TRAP Histomorphometry</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Cancellous (trabecular) bone volume is the percent of the total marrow cavity that is occupied by cancellous bone (both mineralized and non-mineralized) measured by tartrate-resistant acid phosphatase (TRAP) staining histomorphometry.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available cancellous bone volume data.</population>
          <units>percentage of total bone tissue volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 13, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.678" spread="7.270"/>
                    <measurement group_id="O2" value="15.606" spread="6.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="17.631" spread="4.387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Surface Density</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Surface density is calculated by total bone (trabecular) surfaces / total tissue volume.</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available surface density data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Surface Density</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Surface density is calculated by total bone (trabecular) surfaces / total tissue volume.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available surface density data.</population>
          <units>mm²/mm³</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 13, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.009" spread="0.486"/>
                    <measurement group_id="O2" value="1.807" spread="0.486"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="2.472" spread="0.506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Osteoblast - Osteoid Interface</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Osteoblast - osteoid interface is calculated as osteoblast surface / osteoid surface * 100.</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available osteoblast - osteoid interface data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Osteoblast - Osteoid Interface</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Osteoblast - osteoid interface is calculated as osteoblast surface / osteoid surface * 100.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available osteoblast - osteoid interface data.</population>
          <units>percentage of osteoid surface</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 13, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.124" spread="34.879"/>
                    <measurement group_id="O2" value="17.813" spread="28.381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="5.951" spread="15.223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Osteoid Surface</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Osteoid surface is the percent of bone surface covered in osteoid.</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available osteoid surface data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Osteoid Surface</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Osteoid surface is the percent of bone surface covered in osteoid.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available osteoid surface data.</population>
          <units>percentage of total bone surface</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 13, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.915" spread="1.382"/>
                    <measurement group_id="O2" value="0.982" spread="2.489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="0.421" spread="1.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Osteoid Thickness</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Osteoid thickness (width) is the mean thickness of osteoid seams on cancellous surfaces. Osteoid thickness is normally &lt;12.5 µm. Increased osteoid thickness suggests abnormal mineralization (osteomalacia).</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available osteoid thickness data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Osteoid Thickness</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Osteoid thickness (width) is the mean thickness of osteoid seams on cancellous surfaces. Osteoid thickness is normally &lt;12.5 µm. Increased osteoid thickness suggests abnormal mineralization (osteomalacia).</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available osteoid thickness data.</population>
          <units>μm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 13, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.139" spread="3.261"/>
                    <measurement group_id="O2" value="4.548" spread="4.973"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="4.108" spread="3.476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Wall Thickness</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Wall thickness is the average thickness of trabecular bone structural units (BSU) and is used to assess the overall balance between resorption and formation.</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available wall thickness data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Wall Thickness</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. Wall thickness is the average thickness of trabecular bone structural units (BSU) and is used to assess the overall balance between resorption and formation.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available wall thickness data.</population>
          <units>μm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 13, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.11" spread="6.08"/>
                    <measurement group_id="O2" value="49.74" spread="10.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="39.59" spread="7.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Eroded Surface/Bone Surface</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
Eroded surface/bone surface is the percentage of bone surface occupied by eroded (resorption) cavities (Howships lacunae), with or without osteoclasts.</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available eroded surface/bone surface data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Eroded Surface/Bone Surface</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
Eroded surface/bone surface is the percentage of bone surface occupied by eroded (resorption) cavities (Howships lacunae), with or without osteoclasts.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available eroded surface/bone surface data.</population>
          <units>percentage of bone surface</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 13, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.414" spread="0.701"/>
                    <measurement group_id="O2" value="0.328" spread="0.613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="0.511" spread="0.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Osteoclast Number - Length Based</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
Osteoclast number was measured by quantitative histomorphometry and is expressed per mm of bone.</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available osteoclast number data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Osteoclast Number - Length Based</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
Osteoclast number was measured by quantitative histomorphometry and is expressed per mm of bone.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available osteoclast number data.</population>
          <units>1/mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 13, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.086" spread="0.119"/>
                    <measurement group_id="O2" value="0.107" spread="0.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="0.074" spread="0.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Osteoclast Number - Surface Based</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
Osteoclast number was measured by quantitative histomorphometry and is expressed per 100 mm of bone surface area.</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available osteoclast number data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Osteoclast Number - Surface Based</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
Osteoclast number was measured by quantitative histomorphometry and is expressed per 100 mm of bone surface area.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available osteoclast number data.</population>
          <units>1/100 mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 13, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="11.9"/>
                    <measurement group_id="O2" value="10.7" spread="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="7.4" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Osteoclast Number by TRAP - Length Based</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
Osteoclast number was measured using TRAP staining and is expressed per mm of bone.</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available osteoclast number data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Osteoclast Number by TRAP - Length Based</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
Osteoclast number was measured using TRAP staining and is expressed per mm of bone.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available osteoclast number data.</population>
          <units>1/mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 13, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.096" spread="0.134"/>
                    <measurement group_id="O2" value="0.110" spread="0.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="0.077" spread="0.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Osteoclast Number by TRAP - Surface Based</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
Osteoclast number was measured using TRAP staining and is expressed per 100 mm of bone surface.
Da</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available osteoclast number data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Osteoclast Number by TRAP - Surface Based</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
Osteoclast number was measured using TRAP staining and is expressed per 100 mm of bone surface.
Da</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available osteoclast number data.</population>
          <units>1/100 mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 13, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="13.4"/>
                    <measurement group_id="O2" value="11.0" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="7.7" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Single-label Surface</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. A single label is deposited if formation either started or ended during the interval between the uses of the two courses of tetracycline administration. Single-label surface is expressed as a percentage of total bone surface.</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available single-label surface data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Single-label Surface</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. A single label is deposited if formation either started or ended during the interval between the uses of the two courses of tetracycline administration. Single-label surface is expressed as a percentage of total bone surface.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available single-label surface data.</population>
          <units>percentage of bone surface</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 5, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.304" spread="0.302"/>
                    <measurement group_id="O2" value="0.643" spread="0.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="0.611" spread="0.726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Double-label Surface</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. The presence of double labels indicates that normal bone mineralization was actively occurring over the entire labeling interval. Double-label surface is expressed as a percentage of total bone surface.</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available double-label surface data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Double-label Surface</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. The presence of double labels indicates that normal bone mineralization was actively occurring over the entire labeling interval. Double-label surface is expressed as a percentage of total bone surface.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available double-label surface data.</population>
          <units>percentage of bone surface</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 5, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.258" spread="0.207"/>
                    <measurement group_id="O2" value="0.356" spread="0.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="0.106" spread="0.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Mineralizing Surface</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. Total mineralizing surfaces (MS) include all double and half of single-labeled surfaces. MS is expressed as a percentage of total bone surface.</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available mineralizing surface data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Mineralizing Surface</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. Total mineralizing surfaces (MS) include all double and half of single-labeled surfaces. MS is expressed as a percentage of total bone surface.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available mineralizing surface data.</population>
          <units>percentage of bone surface</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 5, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.406" spread="0.323"/>
                    <measurement group_id="O2" value="0.681" spread="0.453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="0.412" spread="0.458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Mineral Apposition Rate</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. The mineral apposition rate (MAR) is the avarage rate at which new bone mineral is being added on any actively forming surface. MAR is calculated as the average distance between visible labels, divided by the labeling interval.</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available mineral apposition rate data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Mineral Apposition Rate</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. The mineral apposition rate (MAR) is the avarage rate at which new bone mineral is being added on any actively forming surface. MAR is calculated as the average distance between visible labels, divided by the labeling interval.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available mineral apposition rate data.</population>
          <units>μm/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 5, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.616" spread="0.219"/>
                    <measurement group_id="O2" value="0.722" spread="0.573"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="0.394" spread="0.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Adjusted Apposition Rate</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. The mineral apposition rate (MAR) is the average rate at which new bone mineral is being added on any actively forming surface. Adjusted MAR is calculated as: (average distance between visible labels / labeling interval) * (total mineralizing surface/total bone surface).</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available adjusted apposition rate data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Adjusted Apposition Rate</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. The mineral apposition rate (MAR) is the average rate at which new bone mineral is being added on any actively forming surface. Adjusted MAR is calculated as: (average distance between visible labels / labeling interval) * (total mineralizing surface/total bone surface).</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available adjusted apposition rate data.</population>
          <units>μm/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 5, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.394" spread="0.471"/>
                    <measurement group_id="O2" value="0.517" spread="0.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="0.818" spread="1.207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Bone Formation Rate - Surface Based</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. Bone formation rate - surface based is the calculated rate at which cancellous bone surface is being replaced annually, derived from the Mineral Appositional Rate * 365 * (relative mineralizing surface / total bone surface).</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available bone formation rate data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Bone Formation Rate - Surface Based</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. Bone formation rate - surface based is the calculated rate at which cancellous bone surface is being replaced annually, derived from the Mineral Appositional Rate * 365 * (relative mineralizing surface / total bone surface).</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available bone formation rate data.</population>
          <units>μm³/μm²/year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 5, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.898" spread="0.706"/>
                    <measurement group_id="O2" value="2.153" spread="2.468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="0.691" spread="0.868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Bone Formation Rate - Volume Based</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. Bone formation rate - volume based is the calculated rate at which cancellous bone volume is being replaced annually, derived from the Mineral Appositional Rate * 365 * (relative mineralizing surface / total bone volume).</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available bone formation rate data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Bone Formation Rate - Volume Based</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. Bone formation rate - volume based is the calculated rate at which cancellous bone volume is being replaced annually, derived from the Mineral Appositional Rate * 365 * (relative mineralizing surface / total bone volume).</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available bone formation rate data.</population>
          <units>percent of bone volume per year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 5, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.454" spread="1.265"/>
                    <measurement group_id="O2" value="3.162" spread="3.773"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="1.071" spread="1.308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Formation Period</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. Formation period (FP) is the mean time required to rebuild a new bone structural unit or osteon from the cement line back to the bone surface at a single location, and is given by wall width / adjusted apposition rate.</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available formation period data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Formation Period</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. Formation period (FP) is the mean time required to rebuild a new bone structural unit or osteon from the cement line back to the bone surface at a single location, and is given by wall width / adjusted apposition rate.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available formation period data.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 5, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="593.5" spread="996.8"/>
                    <measurement group_id="O2" value="287.3" spread="391.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="229.7" spread="512.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Activation Frequency</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. The average time that it takes for a new remodeling cycle to begin on any point on a cancellous surface is called the activation frequency. Activation frequency is calculated as the bone formation rate / wall width.</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available activation frequency data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Activation Frequency</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken. The average time that it takes for a new remodeling cycle to begin on any point on a cancellous surface is called the activation frequency. Activation frequency is calculated as the bone formation rate / wall width.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available activation frequency data.</population>
          <units>/year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 5, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.022" spread="0.019"/>
                    <measurement group_id="O2" value="0.045" spread="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="0.014" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Osteoid Volume</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
Osteoid volume is the percentage of a given volume of bone tissue that consists of unmineralized bone (osteoid).</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available osteoid volume data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Osteoid Volume</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry.
Osteoid volume is the percentage of a given volume of bone tissue that consists of unmineralized bone (osteoid).</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available osteoid volume data.</population>
          <units>percentage of total bone tissue</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 13, 25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.108" spread="0.193"/>
                    <measurement group_id="O2" value="0.146" spread="0.382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="0.048" spread="0.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histomorphometry: Mineralization Lag Time</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken.
Mineralization lag time is the average time interval between osteoid formation and its subsequent mineralization and is calculated by dividing the osteoid width by the apposition rate.</description>
        <time_frame>Month 24 and month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available mineralization lag time data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histomorphometry: Mineralization Lag Time</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histomorphometry. A double tetracycline labeling procedure was used to allow visualization and quantification of sites of new bone formation. Tetracycline was given for two periods of 3 days separated by 14 days where no tetracycline was taken.
Mineralization lag time is the average time interval between osteoid formation and its subsequent mineralization and is calculated by dividing the osteoid width by the apposition rate.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, had at least 1 bone biopsy evaluable for histomorphometry at extension month 24 or extension month 84 and with available mineralization lag time data.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 24 (n = 5, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.9" spread="136.8"/>
                    <measurement group_id="O2" value="54.3" spread="76.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 84 (n = 0, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants in this arm had a bone biopsy evaluable for histomorphometry at month 84</measurement>
                    <measurement group_id="O2" value="52.3" spread="114.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histology at Month 24</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histology to determine if there were any histological abnormalities in the bone. Results are reported for the number of biopsies with normal bone micro-architecture: normal lamellar bone, normal mineralization, and osteoid, and biopsies with abnormal bone histology: osteomalacia, marrow fibrosis, or woven bone.</description>
        <time_frame>Month 24</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, and had at least 1 bone biopsy evaluable for histology at extension month 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histology at Month 24</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histology to determine if there were any histological abnormalities in the bone. Results are reported for the number of biopsies with normal bone micro-architecture: normal lamellar bone, normal mineralization, and osteoid, and biopsies with abnormal bone histology: osteomalacia, marrow fibrosis, or woven bone.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, and had at least 1 bone biopsy evaluable for histology at extension month 24.</population>
          <units>biopsies</units>
          <param>Number</param>
          <units_analyzed>biopsies</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>biopsies</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal lamellar bone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal mineralization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteoid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteomalacia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marrow fibrosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Woven bone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Histology at Month 84</title>
        <description>Bone biopsy samples were prepared according to standard procedures for bone histology to determine if there were any histological abnormalities in the bone. Results are reported for the number of biopsies with normal bone micro-architecture: normal lamellar bone, normal mineralization, and osteoid, and biopsies with abnormal bone histology: osteomalacia, marrow fibrosis, or woven bone.</description>
        <time_frame>Month 84</time_frame>
        <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, and had at least 1 bone biopsy evaluable for histology at extension month 84.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo / Denosumab</title>
            <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab / Denosumab</title>
            <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years in the extension study (total of 10 years treatment).</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Histology at Month 84</title>
          <description>Bone biopsy samples were prepared according to standard procedures for bone histology to determine if there were any histological abnormalities in the bone. Results are reported for the number of biopsies with normal bone micro-architecture: normal lamellar bone, normal mineralization, and osteoid, and biopsies with abnormal bone histology: osteomalacia, marrow fibrosis, or woven bone.</description>
          <population>Participants who enrolled in the bone biopsy substudy, received at least 1 dose of denosumab during the extension study, and had at least 1 bone biopsy evaluable for histology at extension month 84.</population>
          <units>biopsies</units>
          <param>Number</param>
          <units_analyzed>biopsies</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>biopsies</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal lamellar bone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal mineralization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteoid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteomalacia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Marrow fibrosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Woven bone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>84 months</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo/ Denosumab 60 mg Q6M</title>
          <description>Participants who were randomized to placebo in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years.</description>
        </group>
        <group group_id="E2">
          <title>Denosumab/ Denosumab 60 mg Q6M</title>
          <description>Participants who were randomized to denosumab in the core study received a 60 mg subcutaneous injection of denosumab every 6 months for up to seven years (total of 10 years treatment).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="945" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1014" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bone marrow oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Haemorrhagic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Adams-Stokes syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cardiac fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cardiac valve sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Chronic right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Heart valve calcification</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Heart valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Left atrial dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Mitral valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Mitral valve disease mixed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Sinoatrial block</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Supraventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Tachycardia induced cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Tricuspid valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cancer gene carrier</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Congenital ureteric anomaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Corneal dystrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Muscular dystrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Otosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Toxic nodular goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharochalasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cataract diabetic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Detachment of macular retinal pigment epithelium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ectropion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Keratopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Open angle glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Retinal vascular thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Abdominal hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Abdominal rigidity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Acquired oesophageal web</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Anal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Anal sphincter atony</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Coeliac disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Colitis microscopic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Diaphragmatic hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Diverticulum oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Duodenal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Enterocolitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gastroduodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gastrointestinal mucosal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Intestinal angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Intestinal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Intestinal strangulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Large intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Large intestinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Malabsorption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Mesenteric artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Oesophageal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pancreatic necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pancreatitis necrotising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Peritoneal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pharyngo-oesophageal diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Tongue oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Volvulus of small bowel</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Chronic fatigue syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Foreign body reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Incarcerated hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ischaemic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Biliary cirrhosis primary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gallbladder necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gallbladder oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Autoimmune disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bronchitis fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Enterocolitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Haemophilus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hepatic cyst infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Listeriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lymph node tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Mycobacterium avium complex infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pneumonia haemophilus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pneumonia pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Salpingo-oophoritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Small intestine gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Stenotrophomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Subdural empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Tick-borne viral encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Tuberculosis of peripheral lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bone fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cataract traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Dislocation of vertebra</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Eye penetration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Graft complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ilium fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Injury corneal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Limb crushing injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Perineal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Postoperative hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Radiation mucositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Shunt malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Transplant dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ulnar nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Antinuclear antibody positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Blood pressure orthostatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Carcinoembryonic antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Investigation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Protein total decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Vitamin B12 deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired claw toe</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bone disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bone loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Fracture pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Kyphosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Monarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Morphoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Muscle disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Nodal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Osteoarthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Plica syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Sacroiliitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Seronegative arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Sjogren's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Spondyloarthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Synovial disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Adenosquamous cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Adrenal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Anal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Benign gastrointestinal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Benign hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Benign lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Benign neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Benign pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Benign salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Benign vulval neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Carcinoma in situ of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Central nervous system lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Colorectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Dermatofibrosarcoma protuberans</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Follicular thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Gingival cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hairy cell leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Invasive breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Invasive papillary breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Laryngeal papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Leiomyosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lentigo maligna</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lip neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of spinal cord</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Malignant peritoneal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Malignant urinary tract neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Mesothelioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Metastatic carcinoma of the bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Metastatic gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Monoclonal gammopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Muscle neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Myeloproliferative disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Neuroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Nodular fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Oral neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ovarian cancer stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ovarian epithelial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ovarian fibroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pelvic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Phyllodes tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Polycythaemia vera</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Rectal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Rectosigmoid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ureteric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Vulval cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acoustic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Akinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Carotid artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cerebral artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cerebral atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cerebral microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cerebral thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cervicogenic headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cubital tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Diabetic hyperosmolar coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Mononeuropathy multiplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Motor neurone disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pseudoradicular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pyramidal tract syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Radicular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Radiculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Senile dementia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Tarsal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Thrombotic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Vascular headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Emotional distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Schizophrenia, paranoid type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bladder irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Calculus urethral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cystitis interstitial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Mixed incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Urethral disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Urge incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Colpocele</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Endometrial atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Endometrial metaplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Female genital tract fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Fibrocystic breast disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Genital prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Mammary duct ectasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Uterine cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Vaginal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Vulval leukoplakia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Bronchomalacia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Laryngeal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Mediastinal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Nasal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Painful respiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Tonsillar cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Tracheomalacia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lichen sclerosus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Lichenoid keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Activities of daily living impaired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Physical assault</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Anticoagulant therapy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Arthrodesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Benign tumour excision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker replacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Chemotherapy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Joint arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Rehabilitation therapy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Spinal decompression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Urethral operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Arterial disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Embolism venous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Femoral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Phlebolith</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Subclavian artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Vasculitis necrotising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1809" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="1920" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="138" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="140" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="319" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="317" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="206" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="226" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="212" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="192" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="372" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="385" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="167" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="242" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="250" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="176" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="240" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="268" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="215" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="200" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="527" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="541" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="501" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="493" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="197" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="231" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="332" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="355" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="264" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="293" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="163" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="2343"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="143" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="172" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="460" subjects_at_risk="2206"/>
                <counts group_id="E2" subjects_affected="498" subjects_at_risk="2343"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

